HUTCHMED (China) Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG4672N1198
HKD
23.56
-0.32 (-1.34%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

  • Poor long term growth as Operating profit has grown by an annual rate 12.33% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -888.56
2

Risky -

3

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

HKD 20,465 Million ()

stock-summary
P/E

6.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.03

stock-summary
Return on Equity

37.76%

stock-summary
Price to Book

2.12

Revenue and Profits:
Net Sales:
589 Million
(Quarterly Results - Jun 2021)
Net Profit:
-462 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.51%
0%
12.51%
6 Months
-8.68%
0%
-8.68%
1 Year
-6.32%
0%
-6.32%
2 Years
-12.09%
0%
-12.09%
3 Years
14.09%
0%
14.09%
4 Years
-20.41%
0%
-20.41%
5 Years
0%
0%
0.0%

HUTCHMED (China) Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
22.83%
EBIT Growth (5y)
12.33%
EBIT to Interest (avg)
-888.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.69
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
3.79%

Valuation key factors

Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
2.14
EV to EBIT
-69.61
EV to EBITDA
-183.11
EV to Capital Employed
-32.38
EV to Sales
2.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
37.76%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'21 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2021 is 37.61% vs 9.05% in Jun 2020",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2021 is -81.56% vs -33.26% in Jun 2020",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'21",
        "Jun'20",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "588.70",
          "val2": "427.80",
          "chgp": "37.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-625.40",
          "val2": "-354.00",
          "chgp": "-76.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-461.90",
          "val2": "-254.40",
          "chgp": "-81.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,062.40%",
          "val2": "-827.50%",
          "chgp": "-23.49%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -13.04% vs -25.05% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 1,098.29% vs -62.38% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,276.20",
          "val2": "4,917.40",
          "chgp": "-13.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-425.50",
          "val2": "-254.50",
          "chgp": "-67.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "22.30",
          "val2": "22.40",
          "chgp": "-0.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.70",
          "val2": "-37.50",
          "chgp": "98.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3,568.50",
          "val2": "297.80",
          "chgp": "1,098.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-99.50%",
          "val2": "-71.30%",
          "chgp": "-2.82%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'21 - YoYstock-summary

Jun'21
Jun'20
Change(%)
Net Sales
588.70
427.80
37.61%
Operating Profit (PBDIT) excl Other Income
-625.40
-354.00
-76.67%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-461.90
-254.40
-81.56%
Operating Profit Margin (Excl OI)
-1,062.40%
-827.50%
-23.49%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2021 is 37.61% vs 9.05% in Jun 2020

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2021 is -81.56% vs -33.26% in Jun 2020

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
4,276.20
4,917.40
-13.04%
Operating Profit (PBDIT) excl Other Income
-425.50
-254.50
-67.19%
Interest
22.30
22.40
-0.45%
Exceptional Items
-0.70
-37.50
98.13%
Consolidate Net Profit
3,568.50
297.80
1,098.29%
Operating Profit Margin (Excl OI)
-99.50%
-71.30%
-2.82%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -13.04% vs -25.05% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 1,098.29% vs -62.38% in Dec 2024

stock-summaryCompany CV
About HUTCHMED (China) Ltd. stock-summary
stock-summary
HUTCHMED (China) Ltd.
Pharmaceuticals & Biotechnology
Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.
Company Coordinates stock-summary
Company Details
22Nd Floor Hutchison House, 10 Harcourt Road None : 00000
stock-summary
Tel: 852 2121388844 852 21218200
stock-summary
Registrar Details